Clinical trials: Military Personnel
PTSD
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is effective in U.S. military veterans with at least moderate chronic PTSD.
- Trial name
- MPVA6 (NCT04784143)
- Testing
- Midomafetamine, Psychotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine.
- Trial name
- AtEase (NCT02277704)
- Testing
- TNX-102 SL
- Where
- 23 sites in United States
- Volunteers
- 245 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition.
- Trial name
- P202 (NCT02421679)
- Testing
- TNX-102 SL
- Where
- 22 sites in United States
- Volunteers
- 159 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Atrial Fibrillation
The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis
The purpose of this study is to assess the safety and effectiveness of newly initiated dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in comparison to newly initiated rivaroxaban users and newly…
- Trial name
- NCT03026556
- Testing
- Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
- Where
- United States
- Volunteers
- 42,534 people
- Sponsor
- Boehringer Ingelheim
PTSD
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine.
- Trial name
- HONOR (NCT03062540)
- Testing
- TNX-102 SL
- Where
- 44 sites in United States
- Volunteers
- 358 people
- Sponsor
- Tonix Pharmaceuticals, Inc.